184 related articles for article (PubMed ID: 12679924)
1. Is laparoscopy an advantage in the diagnosis of cirrhosis in chronic hepatitis C virus infection?
Wietzke-Braun P; Braun F; Schott P; Ramadori G
World J Gastroenterol; 2003 Apr; 9(4):745-50. PubMed ID: 12679924
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
[TBL] [Abstract][Full Text] [Related]
3. High Prognostic Value of Mini-Laparoscopy for Advanced Liver Disease-Related Complications in Patients with HCV Infection.
Zizer E; Backhus J; Bohl S; Braun A; Baturina I; Klass D; Dikopoulos N; Seufferlein T; Dollinger M
Digestion; 2016; 94(2):114-122. PubMed ID: 27705965
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
[TBL] [Abstract][Full Text] [Related]
5. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.
Bruno S; Battezzati PM; Bellati G; Manzin A; Maggioni M; Crosignani A; Borzio M; Solforosi L; Morabito A; Ideo G; Podda M
J Hepatol; 2001 May; 34(5):748-55. PubMed ID: 11434622
[TBL] [Abstract][Full Text] [Related]
6. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
7. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
[TBL] [Abstract][Full Text] [Related]
8. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
[TBL] [Abstract][Full Text] [Related]
9. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.
Aghemo A; Rumi MG; Monico S; Prati GM; D'Ambrosio R; Donato MF; Colombo M
Antivir Ther; 2009; 14(4):577-84. PubMed ID: 19578243
[TBL] [Abstract][Full Text] [Related]
10. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Vezali E; Aghemo A; Colombo M
Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
[TBL] [Abstract][Full Text] [Related]
11. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
12. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
Maylin S; Laouénan C; Martinot-Peignoux M; Panhard X; Lapalus M; Nicolas-Chanoine MH; Bedossa P; Asselah T; Marcellin P
J Clin Virol; 2012 Jan; 53(1):43-7. PubMed ID: 22099210
[TBL] [Abstract][Full Text] [Related]
13. [Safety of pegylated interferon in patients with hepatitis C virus induced cirrhosis].
Gasztonyi B; Pár G; Pár A; Hunyady B
Orv Hetil; 2005 Nov; 146(48):2431-4. PubMed ID: 16408382
[TBL] [Abstract][Full Text] [Related]
14. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
15. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S
J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
Floreani A; Baldo V; Rizzotto ER; Carderi I; Baldovin T; Minola E
J Clin Gastroenterol; 2008 Jul; 42(6):734-7. PubMed ID: 18285717
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
